ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1172

Effect of Hemodiafiltration with Medium Cut-Off Dialyzer on Uremic Toxins Removal

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Lopez Gil, Jose S., National Institute of Cardiology, Ignacio Chávez, Mexico, Mexico City, CDMX, Mexico
  • Armenta álvarez, Armando, National Institute of Cardiology, Ignacio Chávez, Mexico, Mexico City, CDMX, Mexico
  • Osuna Padilla, Ivan Armando, Centro de Investigacion en Enfermedades Infecciosas CIENI, Mexico City, CDMX, Mexico
  • Grobe, Nadja, Renal Research Institute, New York, New York, United States
  • Tao, Xia, Renal Research Institute, New York, New York, United States
  • Chao, Joshua Emmanuel, Renal Research Institute, New York, New York, United States
  • Raimann, Jochen G., Renal Research Institute, New York, New York, United States
  • Thijssen, Stephan, Renal Research Institute, New York, New York, United States
  • Dias, Gabriela Ferreira, Renal Research Institute, New York, New York, United States
  • Peng, Peiying, Renal Research Institute, New York, New York, United States
  • Wang, Xiaoling, Renal Research Institute, New York, New York, United States
  • Garza, Hector Alejandro Perez Grovas, National Institute of Cardiology, Ignacio Chávez, Mexico, Mexico City, CDMX, Mexico
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
  • Madero, Magdalena, National Institute of Cardiology, Ignacio Chávez, Mexico, Mexico City, CDMX, Mexico
Background

To our knowledge no study has ever evaluated the use of middle cut-off membranes (MCO) with online hemodiafiltration (OL-HDF). This study aims to show if the combination of OL-HDF with MCO can achieve a higher reduction ratio of some uremic toxins in comparison to regular OL-HDF

Methods

Patients from our hemodialysis unit were treated twice with four different modalities, namely combinations of post-dilutional OL-HDF or hemodialysis (HD) with a high-flux dialyzer (CordiaxFX120, area 2.5 m2) or the MCO (Theranova 400; area 1.7 m2), respectively. We analyzed the reduction ratios (RR) of erythropoietin, beta2-microglobulin (B2M), phosphate, and urea.

Results

Twelve anuric patients were studied (6 females; mean age 43.818.5 years; HD vintage 35.2 ± 27.8 months.) Mean blood flow (Qb) was 367 23 ml / min, dialysate flow (Qd) was 493 57 ml / min, ultrafiltration volume was 2382 5683 ml.
B2M RR of HDF+HiFlux was higher than HD+MCO (p=0.003), and HDF+MCO vs. HD+MCO (p=0.029). There was no difference in EPO, phosphate, and urea RR between any of the four groups.

Conclusion

Adding a medium cut-off (MCO) dialyzer to HDF does not add benefit. The B2M RR with HiFlux exceeds the one of a MCO dialyzer. HDF provides benefit over HD regarding the B2M RR regardless of the dialyzer used.

Funding

  • Commercial Support